tirzepatide and parkinson's disease GLP-1/GIP dual agonist alleviates mice model of by promoting mitochondrial homeostasis Targeting Ferroptosis in Parkinson's: Repurposing

83% of adults taking Wegovy lost 5% or more weight, compared to 31% taking a placebo 66% of adults taking Wegovy lost 10% or more weight, compared to 12% taking a placebo 48% of adults taking Wegovy lost 15% or more weight, compared to 5% taking a placebo 30% of people taking Wegovy lost 20% or more weight, compared to 2% of people taking a placebo Wegovy can be prescribed for adults with a BMI over 30, or a BMI over 27 with weight-related conditions such as high blood pressure, heart disease or sleep apnoea

Dosage should be initiated at a low level and gradually increased based on patient response and tolerance

Nausea affects 1620% of users , with some also experiencing diarrhea and vomiting

Neuroscience 77, 257270

tirzepatide, and how providers differ

In 4,622 prostate cancer patients identified in the SEER-Medicare database, 23.5% of prostate cancer patients were also on anti-diabetic drugs (patients diagnosed with prostate cancer and initiated on abiraterone or enzalutamide between September 1, 2012 and June 2, 2017) (39) (Figure 1A)